Scancell's mission is to develop products that stimulate the immune system to treat or prevent cancer.
DATE FIRST INVESTED
Scancell’s mission is to develop products that stimulate the immune system to treat or prevent cancer.
In December 2006, Scancell sold its pipeline of direct killing monoclonal antibodies to Arana Therapeutics, an Australian biopharmaceutical company. The deal allowed Scancell to focus its efforts entirely on its innovative ImmunoBody® and Moditope® cancer vaccine programmes.
Scancell’s first clinical candidate drug, ImmunoBody® is a DNA vaccine which is being developed for the treatment of melanoma.
Scancell began trading on AIM in 2008.